N-myristoyltransferases: structure, function, disease, and inhibitors
Blocking a protein overactive in cancer cells offers a new drug target researchers are actively developing with precision antibody approaches.
This Drug Discovery Today review covers N-myristoyltransferases as emerging cancer drug targets, detailing their structure, catalytic mechanisms, and inhibitor development. It highlights NMT1 overexpression in cancer and the potential for selective NMT inhibitors and antibody-drug conjugate combinations.
What the study was
- Study design
- Narrative review
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Drug Discovery Today
Why it surfaced
Interesting drug target review in DDT but early-stage. No clinical data yet.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.